Elevated desmoglein‐2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high‐risk cytogenetics and a distinct gene expression profile

Ähnliche Einträge

• Early M‐protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high‐risk cytogenetic multiple myeloma
  von: Huihui Zhu, et al.
  Veröffentlicht: (2024)
• Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non‐Hodgkin lymphomas
  von: Coura Fall, et al.
  Veröffentlicht: (2026)
• Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data
  von: Noa Biran, et al.
  Veröffentlicht: (2025)
• Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression
  von: Wataru Kuroki, et al.
  Veröffentlicht: (2025)
• Methodological considerations in prognostic marker studies for mycosis fungoides
  von: Jinlin Liu
  Veröffentlicht: (2026)